Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Bluetooth

Eli Lilly HQ

Lilly and Immunocore ink immunotherapy R&D deal

Firms will test new joint therapy in patients with melanoma

- PMLiVE

Is telehealth delivering on its promises?

How well are new digital technologies being used to help patients see their doctors online

- PMLiVE

Ten new medicines recommended in Europe

Includes double approvals for rare disease specialist Alexion and Novartis

Wearables: the tangible product of the patient revolution

As the relationship between the patient and his doctor evolve, we look at how new technology is playing its part

- PMLiVE

AstraZeneca and its diabetes plans

Director of marketing Chris Boulton is bullish on its prospects

- PMLiVE

AZ and Inserm collaborate on diabetes and kidney disease

Three-year partnership will look at new therapeutic approaches

- PMLiVE

Novo Nordisk becomes diabetes drug sales leader

Supplants former frontrunner Sanofi - but both firms set for a tough 2015

Eli Lilly HQ

Lilly and Incyte’s baricitinib aces phase III trials

Supports its potential as a therapy for rheumatoid arthritis

- PMLiVE

Bayer sells diabetes division to Panasonic Healthcare

€1.02bn sale includes Contour electronic meters and other medical devices

- PMLiVE

Sanofi will resubmit Lyxumia for FDA approval in Q3

Follows the GLP-1 agonist's all-clear by ELIXA cardiovascular safety study

- PMLiVE

Merck & Co’s diabetes drug Januvia cleared by CV safety trial

Concerns over the DPP-4 inhibitor 'put to bed' by TECOS cardiovascular trial

- PMLiVE

Rivals look to put pressure on Sanofi’s Lantus

Novo Nordisk and Lilly claim clinical benefitsover top-selling diabetes drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links